OBJECTIVES: To investigate the expression of NKG2A on cytotoxic natural killer (NK) cells in HIV-1-infected patients. DESIGN: A cross-sectional study was conducted to investigate the NKG2A expression on NK cell subsets among HIV-infected individuals at different clinical stages and HIV negative controls. METHODS: 113 HIV-1 infected and 43 uninfected individuals were enrolled in this study. The HIV-1 infected patients were further categorized into three groups, CD4 cell count > 500 cells/microl (n = 44), CD4 cell count of 200-500 cells/microl (n = 49) and CD4 cell count < 200 cells/microl (n = 20). Flow cytometry was used to determine the expression of NKG2A on NK cell subsets. A flow-based assay was employed to quantify the NK cytotoxicity. RESULTS: Fewer cytotoxic NK cells and more dysfunctional NK cells were observed in patients with advanced clinical conditions. Higher NKG2A expression level in cytotoxic NK subset were found in later stages HIV infection, 25.6% in groups with CD4 cell count > 500 cells/microl, 40.9% in groups with CD4 cell count 200-500 cells/microl and 48.3% in groups with CD4 cell count < 200 cells/microl. Lower NK mediated cytotoxicity, which was associated with the decrease in cytotoxic NK cell number and higher NKG2A expression on cytotoxic NK subsets, was found in AIDS patients compared with patients at early stage of infection. A reverse association between the percentage of NKG2A positive cells in cytotoxic NK subset and CD4 cell count was observed in all HIV-1 infected groups. CONCLUSION: Fewer cytotoxic NK cells and higher NKG2A expression in cytotoxic NK subset was found in patients in late stage HIV infection. Such a phenomenon may relate to the escape of HIV-1-infected CD4+ T cells from being attacked by NK cells.
OBJECTIVES: To investigate the expression of NKG2A on cytotoxic natural killer (NK) cells in HIV-1-infectedpatients. DESIGN: A cross-sectional study was conducted to investigate the NKG2A expression on NK cell subsets among HIV-infected individuals at different clinical stages and HIV negative controls. METHODS: 113 HIV-1 infected and 43 uninfected individuals were enrolled in this study. The HIV-1 infectedpatients were further categorized into three groups, CD4 cell count > 500 cells/microl (n = 44), CD4 cell count of 200-500 cells/microl (n = 49) and CD4 cell count < 200 cells/microl (n = 20). Flow cytometry was used to determine the expression of NKG2A on NK cell subsets. A flow-based assay was employed to quantify the NK cytotoxicity. RESULTS: Fewer cytotoxic NK cells and more dysfunctional NK cells were observed in patients with advanced clinical conditions. Higher NKG2A expression level in cytotoxic NK subset were found in later stages HIV infection, 25.6% in groups with CD4 cell count > 500 cells/microl, 40.9% in groups with CD4 cell count 200-500 cells/microl and 48.3% in groups with CD4 cell count < 200 cells/microl. Lower NK mediated cytotoxicity, which was associated with the decrease in cytotoxic NK cell number and higher NKG2A expression on cytotoxic NK subsets, was found in AIDSpatients compared with patients at early stage of infection. A reverse association between the percentage of NKG2A positive cells in cytotoxic NK subset and CD4 cell count was observed in all HIV-1 infected groups. CONCLUSION: Fewer cytotoxic NK cells and higher NKG2A expression in cytotoxic NK subset was found in patients in late stage HIV infection. Such a phenomenon may relate to the escape of HIV-1-infectedCD4+ T cells from being attacked by NK cells.
Authors: Ambrose H W Wong; Katie Williams; Sharon Reddy; Douglas Wilson; Janet Giddy; Galit Alter; Musie Ghebremichael; Mary N Carrington; Thumbi Ndung'u; Bruce D Walker; Marcus Altfeld; William H Carr Journal: AIDS Res Hum Retroviruses Date: 2010-04 Impact factor: 2.205
Authors: Pavel Bostik; Jaruda Kobkitjaroen; Weining Tang; Francois Villinger; Lara E Pereira; Dawn M Little; Susan T Stephenson; Mark Bouzyk; Aftab A Ansari Journal: J Immunol Date: 2009-03-15 Impact factor: 5.422
Authors: Kuldeep S Cheent; Khaleel M Jamil; Sorcha Cassidy; Mengya Liu; Berenice Mbiribindi; Arend Mulder; Frans H J Claas; Marco A Purbhoo; Salim I Khakoo Journal: Proc Natl Acad Sci U S A Date: 2013-09-30 Impact factor: 11.205
Authors: Zongqi Xia; Qingquan Liu; Christoph T Berger; Brendan T Keenan; Anna Kaliszewska; Patrick C Cheney; Gyan P Srivastava; Irene Wood Castillo; Philip L De Jager; Galit Alter Journal: J Immunol Date: 2012-02-15 Impact factor: 5.426
Authors: Giulia Fregni; Anaenza Freire Maresca; Valérie Jalbert; Anne Caignard; Daniel Scott-Algara; Elisabeth Bordé Cramer; Elisabeth Rouveix; Marie C Béné; Claude Capron Journal: Virol J Date: 2013-01-26 Impact factor: 4.099